The combination of a DYRK1A inhibitor, harmine, together with exendin-4, increases human β cell mass in immunodeficient mice transplanted with human islets by 700% over 3 months of treatment, while also reversing diabetes [80]. The gene discussed is DYRK1A; the disease is diabetes mellitus.